The Wall Street Journal opinion editors recently published an article a liquid biopsy test called Galleri, prior to an upcoming FDA review.
Key Trial Results Driving the Enthusiasm
The article highlights several clinical trial outcomes to demonstrate why the product represents a significant leap forward in preventative healthcare:
- Superior Detection Rates: In a 142,000-patient U.K. National Health Service trial, Galleri “caught four times as many cancers in total than the U.K.’s four recommended screenings for colon, breast, lung and cervical cancer.” A North American study of 36,000 patients found it detected “6.5 times as many cancers as screenings recommended by the U.S. Preventive Services Task Force.”
- Filling Screening Gaps: The test catches hidden threats, as 73% of the cancers detected in the North American study “don’t have recommended screenings.”
- Early Stage Catch: The NHS trial showed the test “increased diagnoses of the 12 most deadly cancers at stages one and two by 16%.” Furthermore, stage four diagnoses “declined 14%,” with reductions growing over time—a strong signal that the test captures malignancies before they advance.
- Life-Saving Staging Shifts: Moving a diagnosis from stage four to stage three drastically changes survival odds. For colon cancer, patients at stage four have an “estimated 11% odds of surviving five years, versus 64% if they are diagnosed at stage three.” Similar survival jumps occur in bladder (“6% vs. 32%”), stomach (“5% vs. 25%”), and ovarian cancer (“16% vs. 32%”).
Technology and Managed Risks
The writer emphasizes that the test relies on genetic sequencing and machine learning to recognize tumor DNA signatures tagged by specific organ origins. As adoption expands, the technology is expected to compound its own effectiveness because “AI will harness more patient data to identify signals with more precision.”
Addressing safety and cost concerns, the author argues that the trade-offs are modest compared to the benefits:
- “Fewer than half of initial positive findings are false alarms.”
- “85% of follow-up evaluations are non-invasive.”
Pushing Back Against Regulatory Delays
The commentary sharply critiques skeptics and FDA critics who demand multi-year mortality trials before granting approval. Requiring such trials would “delay FDA approval by years” and ignore how earlier detection enables pharmaceutical companies to “develop and test medicines in earlier disease stages.” The article concludes that regulators should allow patients and doctors to “weigh the trade-offs” rather than restricting access or forcing patients to pay out-of-pocket prices around $799.
